PALB2 germline pathogenic confers BRCA-like breast risk (~50% lifetime). Olaparib activit...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PALB2-GERMLINE-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | PALB2 germline pathogenic |
| Disease | DIS-BREAST |
| ESCAT tier | IIA |
| Recommended combinations | olaparib (off-label per NCCN, TBCRC-048 evidence), talazoparib (off-label), platinum-based chemo (TNBC) |
| Evidence summary | PALB2 germline pathogenic confers BRCA-like breast risk (~50% lifetime). Olaparib activity reported in PALB2-mutated breast (Tung TBCRC-048: ORR ~82% in HER2-negative metastatic, n=11) but PARPi labels in breast remain BRCA- only. NCCN lists PALB2 as a PARPi-eligible mutation off-label. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing mandatory. PALB2 carriers also face elevated pancreatic and ovarian risk — enhanced surveillance recommended.
Used By
No reverse references found in the YAML corpus.